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LeukemiaIn the last years small RNA molecules, i.e. microRNA (miRNA) encoded bymiR genes, have been found to play
a crucial role in regulating gene expression of a considerable part of plant's and animal's genome. Here, we
report the essential information on biogenesis of miRNAs and recent evidence on their important role in
human diseases. Emphasis has been given to miR-155, since this molecule represents a typical
multifunctional miRNA. Recent data indicate that miR-155 has distinct expression proﬁles and plays a
crucial role in various physiological and pathological processes such as haematopoietic lineage differentia-
tion, immunity, inﬂammation, cancer, and cardiovascular diseases. Moreover, miR-155 has been found to be
implicated in viral infections, particularly in those caused by DNA viruses. The available experimental
evidence indicating that miR-155 is over expressed in a variety of malignant tumors allows us to include this
miRNA in the list of genes of paramount importance in cancer diagnosis and prognosis. Exogenous molecular
control in vivo of miR-155 expression could open up new ways to restrain malignant growth and viral
infections, or to attenuate the progression of cardiovascular diseases.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a class of evolutionarily conserved,
single-stranded non-coding RNA molecules of 19–24 nucleotides that
control gene expression at a post-transcriptional level. They derive
from the metabolic processing of long RNA transcripts encoded bymiR
genes. They have been detected in plants, animal species and viruses,
and are involved in numerous cellular processes including prolifera-
tion, differentiation, apoptosis and metabolism [1]. In most cases,
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ll rights reserved.their capacity of gene or gene cluster silencing. To date they have been
predicted to target and control the expression of at least 30% of the
entiremammalian genome [2]. Of primarymedical importance are the
ﬁndings that deregulated miR gene expression is involved in different
human diseases including cancer [3].
1.1. Biogenesis of miRNA
In the last few years, it has been found that miR genes may be
present either as single units scattered in the genome or may be
organized in gene clusters. A typical example of these gene clusters is
provided by the miR-17-92 cluster, which comprises six miRs (miR-17,
miR-18a, miR-19a, miR-20a, miR-19b-1, miR-92a-1). Clustered miRs
are likely transcribed together in polycistronic transcripts and usually
control mRNAs with related functions. Therefore, genomic regions
around known miR gene locations are particularly promising for
ﬁnding new miRNA-coding DNA sequences [4]. Some miRs can be
grouped as “families”. They have been identiﬁed studying sequence
homology that is mainly present at the 5′ end of mature miRNA [5].
An interesting aspect of miR genes is related to their genome
position. They are mainly located within introns and intergenic
regions, largely composed by non-coding DNA sequences previously
considered as “junk DNA”.
Biogenesis ofmiRNA is a complexmulti-step process starting in the
nucleus and ending in the cytoplasm throughout many post-
transcriptional modiﬁcations. In the ﬁrst step of this process the
RNA polymerase II transcribes miR genes generating primary
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are large transcripts that can contain multiple miRNA sequences
which at this stage are already folded into hairpin structures (Fig. 1).
The nuclear microprocessor that contains the RNase III enzyme Drosha
and a double-stranded-RNA-binding protein DGCR8 (Digeorge syn-
drome critical region gene 8) processes the pri-miRNA into ∼70
nucleotide miRNA precursor known as pre-miRNA. The pre-miRNA
stem–loop structures are then transported to the cytoplasm through
the exportin 5 complex [6]. The cytoplasmic endonuclease Dicer,
complexed with its co-factors TAR RNA-binding protein (TRBP) and
PKR-activating protein (PACT), starts to process the pre-miRNA [7,8].
Dicer cleaves the pre-miRNA stem–loop forming a 21–24 bp duplex
miRNA, which contains 2 nucleotides that overhang at the 3′ of each
strand. One strand is then selected on the basis of the stability of the 5′
end (guide strand) whereas the other strand (passenger strand) is
usually degraded. At this stage the miRNA is loaded into the RNA
induced silencing complex (RISC) containing Argonaute (AGO) proteins
[9,10]. After integration into the active RISC complex, miRNAs base
pair with their complementary mRNA molecules. Degradation of the
target mRNA occurs only when the miRNA and the target mRNA are
exactly (perfect match) or nearly exactly complementary to each
other. This process is the same of the RNA interference induced by
artiﬁcial small interfering RNAs (siRNAs). On the other hand, if the
complementarity between miRNA and target mRNA is only partial
(imperfect match), translation repression will take place. In animals,
miRNAmolecules can bind several target sequences, mainly present at
the 3′ untranslated region (3′UTR) of mRNA with various degrees of
complementarity [11]. It follows that each single miRNA is able to
interact and regulate a large number of genes. It has been estimatedFig. 1. Biogenesis of mature miRNA. Transcription of a miR gene by RNA polymerase II genera
into pre-miRNA by a complex containing Drosha and DGCR8 proteins. Pre-miRNA is exporte
Dicer, TRBP, PACT proteins play themain role. After cleavage by the Dicer complex the resultin
loaded into the RISC to bind the mRNA target. If the complementarity between the 3′UT
complementarity is partial, the translation of the target mRNA is repressed.that a single miRNA molecule is able to bind about 200 different
transcripts [12]. In turn, biogenesis and functions of miRNA are ﬁnely
governed by transcription factors and dynamic cellular signals [13].
1.2. Role of miRNA in diseases
In humans, more than 800 miR genes have been identiﬁed even if
the total number is estimated to be not less than one thousand.
Although research on miRNAs is only at the beginning, it is already
clear that they are involved in a broad-spectrum of diseases, including
cancer. The role of miRNAs in malignant transformation and tumor
progression emerged with the ﬁnding that miR-15a and miR-16 are
located on chromosome 13q14.3 within a 30-kb region that is
frequently deleted in Chronic Lymphocytic Leukemia (CLL) determin-
ing down-regulation of both miRNAs in the majority of the analyzed
CLL cell samples [14]. Interestingly, more than 50% of miR genes were
found to be located at fragile sites or at chromosomal regions showing
ampliﬁcation, deletion or translocation in cancer [15]. Deregulated
miRNA expression has now been associated with several tumor types
including colon, breast, and lung cancer [16,17]. Moreover, altered
miRNA expression has been found in haematological malignancies,
including several types of lymphoma and leukemia [15,18,19]
suggesting that miR genes play a key role as oncogenic or tumor
suppressor genes.
A certain number of miRNAs has also been found to be implicated
in neurological diseases, such as Parkinson's disease (PD) and
Alzheimer's disease (AD). In PD, ﬁbroblast growth factor 20 (FGF20)
was previously identiﬁed as a risk factor in several association studies.
A risk allele stems from a single nucleotide polymorphism in the 3′tes pri-miRNA (with a 5′ 7mG cap and a 3′ poly-A tail) that is processed in the nucleus
d to the cytoplasm and is processed into a duplex miRNA by another complex in which
gmiRNA duplex is unwound and the passenger strand is degraded. ThematuremiRNA is
R mRNA and the miRNA is extensive the target mRNA is degraded, whereas, if the
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microRNA-433. This is followed by increased translation of FGF20
leading to α-synuclein over expression, which has previously been
shown to cause PD [20].
Little is known about the role of miRNAs in AD. A number of
experimental and clinical data suggest that β-amyloid is central to the
pathophysiology of AD and that the β-amyloid precursor protein-
cleaving enzyme 1 (BACE1) is essential for the generation of the
neurotoxic β-amyloid peptide. It has been shown that miR-107 levels
decrease signiﬁcantly in themajority of patients including those at the
early stage of the disease. In a parallel way, the BACE1 mRNA levels
tend to increase as miR-107 levels decrease in the progression of AD.
The 3′UTR of BACE1 mRNA can be targeted in multiple sites by miR-
107 suggesting that miR-107 is one of the multifactorial causes
involved in AD progression [21].
2. Expression and function of miRNA-155
The present minireview focuses on the miR-155 (Fig. 2) since this
molecule represents a typical multifunctional miRNA. To date,
increased evidence points out that miR-155 is involved in numerous
biological processes including haematopoiesis, inﬂammation and
immunity. It is also implicated in the regulation of type 1 Angiotensin
II receptor (AT1R) an important molecule that takes part in renal
function and contraction of vascular smooth muscle.
Deregulation of miR-155 has been found to be associated with
different kinds of cancer, cardiovascular diseases and viral infections.
Since investigation on the functional activity of miR-155 started a few
years ago, it is reasonable to predict that many other functions will be
uncovered in the near future.
MiR-155 maps within and is processed from an exon of a non-
coding RNA transcribed from the B-cell Integration Cluster (BIC)
located on chromosome 21 [22]. BIC shows strong sequence homology
among human, mouse and chicken and is highly, although notFig. 2. Maturation and interaction of miR-155 with a validated mRNA target. (A) Pre-
miR-155 stem–loop structure. Nucleotide sequence of miR-155 RNA duplex is indicated
in pink. (B) Mature single strand miR-155. (C) Example of interaction of miR-155 with
target 3′UTR of mRNA transcript of AT1R gene. In this case, a 50% mismatch has been
found between miR-155 sequence and the major AT1R allele. The arrow indicates the
base that can be substituted by C in the case of single nucleotide polymorphism that is
accompanied by failure of translation control by miR-155 [64].exclusively, expressed in lymphoid organs implying an evolutionary
conserved function.
2.1. Haematopoiesis
More than one miRNA is involved in regulation and differentiation
of cells of haematopoietic origin. MiR-155 is expressed in both
lymphoid and myeloid cells but at different levels depending on the
cell type. Masaki S. and colleagues have shown that during erythroid
differentiation in vitro, puriﬁed human progenitors cells show a
progressive decrease of miR-155 expression, that was found to be 200
fold lower in mature red cells. On the contrary, in the same cells
during the last 12 days of differentiation miR-451 is up-regulated to
270-fold, thus identifying this two miRNAs as key molecules in
erythroid maturation [23].
Georgantas RW III et al. found that a substantial amount of genes
specifying haematopoietic cell differentiation are expressed byCD34+
haematopoietic stem cells (HSC) but are held in check by a number of
miRNAs until differentiation occurs. More exhaustive informationwas
obtained for miR-155. Chemically-induced erythroid and megakar-
yocytic differentiation of K562 cell line was found to be signiﬁcantly
reduced by target cell transduction with miR-155. The inhibitory
function of this miR gene was conﬁrmed in in vitro cultured normal
HSCs in which transduction with miR-155 generated 5-fold less
myeloid and 3-fold less erythroid colonies. Furthermore, in thismodel,
colonies were much smaller than controls [24]. These results strongly
suggest that miR-155 is an essential molecule in the control of human
protein translation in both myelopoiesis and erythropoiesis.
2.2. Inﬂammation
The inﬂammatory response to infections involves the induction of
several hundred genes, a process that must be ﬁnely regulated to
achieve pathogen clearance and to prevent the pathological con-
sequences of a deregulated gene expression.
The possibility that environmental factors, such as inﬂammatory
ligands, may alter miR gene expression is just beginning to be
explored. Recently, miR-155 has been identiﬁed and characterized as
a component of the primary macrophage response to different types
of inﬂammatory mediators. For instance, it has been shown that
miR-155 is induced by bacterial lipopolysaccharide (LPS) in a human
monocytic cell line [25]. Inﬂammatory mediators including IFN-β
polyriboinosinic–polyribocytidylic acid (poly IC) or Tumor Necrosis
Factor-α (TNF-α) can induce miR-155 in macrophages and mono-
cytes. Furthermore, pharmacological inhibition of the c-Jun N-
terminal kinase (JNK) blocks induction of miR-155, suggesting that
miR-155-inducing signals use the JNK pathway [26]. Moreover, it has
been hypothesized that the regulation of miR-155 levels could be
controlled, at least in part, by the mitogen-activated protein kinase
(MAPK) pathway [26].
Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune
disorder characterized by activation of the immune system at joint
level, where it leads to inﬂammation and irreversible damage.
Stanczyk et al. found the expression of miR-155 and miR-146a in
synovial ﬁbroblasts and tissue of RA patients higher than that
detectable in patients with osteoarthritis. They observed a further
up-regulation of miR-155 after stimulation in vitro with TNF-α, IL-1β
and toll-like receptor ligand (LPS, poly IC). Moreover, in RA synovial
ﬁbroblasts these authors found that over expression of miR-155
induced by LPS, IL-1β and TNF-α, down-regulates production of
matrix metalloproteinase (MMPs) 1 and 3, that are important markers
of the destructive and inﬂammatory effects of RA. Interestingly, the
expression of miR-155 in CD14+ monocytes/macrophages present in
the synovial ﬂuid of RA patients was found 4.4 fold higher than that
detectable in peripheral blood CD14+ cells. In summary, miR-155
might function as a protective miRNA that locally down-regulates the
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inﬂammation [27].
2.3. Immunity
BIC/miR-155 expression is greatly increased in activated B and T
cells, as well as in activated macrophages and dendritic cells. On the
other hand, miR-155 was found to be required for lymphocyte
development and generation of B and T cell responses in vivo after
BCR or TCR activation. In fact, BIC/miR155 deﬁcient mice immunized
with the tetanus toxin fragment C protein are characterized by a
reduced production of IgM and switched antigen-speciﬁc antibodies.
Moreover, splenocytes of immunizedmice failed to produce signiﬁcant
levels of IL-2 and IFN-γ thus indicating an important role for miR-155
during both T cell independent and dependent responses. In addition
to defective B and Tcell immunity, miR-155 deﬁcientmice have shown
an impaired antigen-presenting function of dendritic cells [28].
Comparable results were obtained by Thai et al. [29] using a similar
experimental mousemodel. They showed that miR-155 deﬁcient mice
had reduced germinal center function, T cell dependent antibody
response and cytokine production. The authors stressed the ﬁnding
that immune responses in miR-155-deﬁcient mice is diverted towards
a Th2 pattern, with substantial increase of IL-10, a cytokine endowed
with immunodepressive activity against cell-mediated responses.
The intrinsic requirement for miR-155 was studied in detail in
antigen B-cell responses. In miR-155-deﬁcient mice, B cells generate
reduced extrafollicular and germinal center responses and fail to
produce high-afﬁnity IgG1 antibodies [30]. Microarray analysis of
wild-type and miR-155-deﬁcient B cells activated under conditions
that promote class switching to IgG1, reveals that miR-155 regulates
the expression of a substantial number of target genes, many of which
can be predicted by in silico analysis. One of the genes highly
expressed in miR-155-deﬁcient B cells encodes for the transcription
factor PU.1 which has a highly conserved miR-155 binding site in its 3′
UTR. PU.1 is known to be important in many aspects of haematopoi-
esis, in particular for the early activation of B cells and regulation of B-
cell function. Moreover, PU.1 over expression in wild-type B cells
results in reduced numbers of IgG1-switched cells. These results
strongly suggest that miR-155 is required for inducing down-
regulation of PU.1 in antigen driven maturation and IgG1 class-
switched differentiation in B cells [30].
Recently, two independent groups identiﬁed the enzyme activa-
tion-induced cytidine deaminase (AID) as another important target of
miR-155 in vivo. AID deaminates cytosine residues and introduces U:G
mismatches in DNA. Therefore the enzyme promotes high frequency
mutations that are physiologically involved in somatic hypermutation
required for high-afﬁnity IgG antibody repertoire in antigen-activated
B cells. Solid experimental evidence indicates that miRNA-155 is a
negative regulator of AID [31,32]. Nucleotide substitutions in the miR-
155 binding site located in the 3′UTR of AID gene prolongs the half-life
of its transcript and increases the amount of AID protein. Therefore,
one would expect that B cells of miR-155 deﬁcient mice would be
excellent producers of high-afﬁnity IgG antibodies. However, as
previously mentioned, in vivo mouse studies provided just opposite
results [30], pointing out that the high-afﬁnity antibody response is
ﬁnely regulated by different gene products presumably inﬂuenced by
miR-155 in different and still not entirely understood ways.
Tili et al. investigated the relationship betweenmiR-155 and innate
immunity focusing their attention on a microbial-associated activat-
ingmolecule such as LPS and the pro-inﬂammatory cytokine TNF-α. In
LPS-stimulated macrophages TNF-α is one of the main cytokines
involved in the innate immunity response. Studies on a mouse
macrophage/monocyte leukemia cell line (i.e. Raw 264.7 cells)
showed that enhancement of TNF-α by LPS is accompanied by
down-regulation of miR-125b and up-regulation of miR-155. A similar
expression pattern has been also found in C57BL/6mice subjected to i.p. inoculation with LPS [33]. A number of studies suggest that miR-
125b directly targets the 3′UTR of TNF-α transcripts. It follows that
down-regulation of miR-125b induced by LPS removes, at least in part,
the inhibitory effect of this miRNA on TNF-α translation. On the other
hand, up-regulation of miR-155 provoked by exposure to LPS,
enhances TNF-α production. In this case, however, the underlying
mechanism has not been fully clariﬁed. It has been hypothesized that
miR-155 could increase directly TNF-α levels by augmenting
transcript stability through binding to its 3′UTR. Alternatively, miR-
155 could target gene transcripts coding for proteins that are known to
be repressor of TNF-α translation.
The correlation between miR-155 and responses induced by LPS
are consistent with the ﬁnding that miR-155 targets transcripts coding
for proteins involved in LPS/TNFα signaling including the Fas-
associated death domain protein (FADD), the IkB kinase epsilon (IKKɛ)
and the receptor (TNFR superfamily)-interacting serine–threonine
kinase1 (RIPK1). Moreover, in vivo studies showed that transgenic
mice over expressing miR-155 in B-cell lineage (Eμ-miR-155) produce
more TNF-αwhen challenged with LPS and are hypersensitive to LPS/
D-galactosamine induced septic shock [33] with respect to their
normal counterparts. All together, these data suggest that the
interplay between miR-155 and LPS/TNF-α may be implicated in
the endotoxin shock.
3. miR-155 and neoplastic diseases
There are several lines of evidence that miR-155 is over expressed
in a number of neoplastic diseases and that it plays a signiﬁcant role in
the process of carcinogenesis, acting predominantly as an oncomir
[34]. Several mechanisms have been suggested to explain this
biological activity. For example, miR-155 was found to be one of the
most potent miRNA suppressing apoptosis in human T cell leukemia
Jurkat cells and in MDA-MB-453 breast cancer cells. The mechanism
underlying the effect of miR-155 could be ascribed to a blockade of
caspase-3 activity [35]. In fact, over expression of miR-155 is followed
by a substantial decrease of tumor protein 53-induced nuclear protein 1
(TP53INP1), that is a nuclear protein able to induce cell cycle arrest
and apoptosis through caspase-3 activation [36]. This role in apoptosis
could be responsible for the oncogenicity of miR-155 in several types
of cancer.
3.1. miR-155 and B-cell Lymphoma
The BIC gene was originally described as a common site of viral
DNA integration in virus-induced lymphomas in chicken. In humans,
BIC RNA levels are low in normal lymphoid tissues but increase in
various B-cell malignancies, including Hodgkin's Lymphoma and
some subtypes of Non Hodgkin's Lymphoma [37,38].
Hodgkin's Lymphoma is clinically characterized by the orderly
spread of disease from one lymph node group to another and by the
development of systemic symptoms in an advanced stage of the
disease. High expression of BIC/miR-155 was observed in Reed–
Sternberg cells of Hodgkin's Lymphoma [39] and in the lymphocytic
and histiocytic cells of the variant nodular lymphocyte-predominant
Hodgkin's Lymphoma [37].
The majority of Non Hodgkin's Lymphomas does not express BIC/
miR-155. However, BIC was observed in Primary Mediastinal B-cell
Lymphoma (PMBL), in Diffuse Large B-cell Lymphoma (DLBCL) [37]
and in children's Burkitt's Lymphoma [40].
PMBL is a rare form of Non Hodgkin's Lymphoma that origins from
a rare type of B-cell lymphocytes in the thymus gland. Presence of BIC/
miR-155 was detected in frozen tissues and PMBL cell lines [37].
DLBCL is the most common form of adult Non Hodgkin's
lymphoma accounting for nearly 40% of all lymphoid tumors. DLBCL
is characterized by marked clinical and pathological heterogeneity
that is reﬂected at the molecular level. Gene expression and immuno-
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molecular subtypes of DLBCL related to the type of cell they arise from,
i.e. germinal center B cell-like (GCB) and activated B cell-like (ABC).
Prognosis is worse in the ABC than in GCB subtype. BIC/miR-155 is
expressed at a higher level in ABC-type than in GCB-type cell lines,
suggesting that the quantiﬁcation of this miRNA may have a role in
establishing the prognosis [18]. Recently 42 genes down-regulated in
ABC subtypes were correlated with the high expression of miR-155.
Although only nine of them are predicted targets of this miRNA, an
indirect effect ofmiR-155 on the other genes cannot be excluded. Some
of these genes regulated bymiR-155 are implicated in immune system
homeostasis and at least three of them have oncogenic effects [41].
Burkitt's Lymphoma is a very fast growing form of Non Hodgkin's
Lymphoma. In tumor cells of 11 children with Burkitt's Lymphoma,
MetzlerM. et al. [40] found high expression of miR-155, that wasmore
pronounced than that detectable in Acute Lymphoblastic Leukemia
(ALL) of children or in mononuclear cells of healthy donors. However,
these results were not conﬁrmed by other authors [42]. To solve this
controversy, different Burkitt's Lymphoma cell lines were induced to
express BIC by BCR stimulation. It was shown that BIC up-regulation is
not accompanied by increase of miR-155 expression suggesting two
levels of regulation of mature miR-155 expression, either at transcrip-
tional and at processing levels [43]. However, a recent study failed to
show the presence of an intrinsic blockade of BIC/miR-155 processing
in cultured or primary Burkitt's Lymphoma cells [44].
As previously mentioned, miR-155 targets efﬁciently the 3′UTR
sequence of AID gene [31,32]. This biochemical event reveals a
potentially different biological role of miR-155. Although AID activity
is predominantly restricted to IgG genes, off-target lesions of DNA
could be responsible of double-strand breaks favouring oncogenic
translocation, including Myc translocation [32]. Since miR-155 is a
negative modulator of AID levels, it is reasonable to hypothesize that
this miRNA could reduce the chances of malignant transformation in
selected tissues that can be targeted by AID-mediated mutagenesis
[32]. On the other hand, a direct evidence that miR-155 is involved in
B-cell malignancy has been obtained experimentally in vivo in
transgenic mice carrying miR-155 that is speciﬁcally over expressed
in B-cell lineage [45]. In this experimental model miR-155 expression
is under the control of a VH promoter and is active in the late stage of
B-cell development. Transgenic mice exhibit initially a preleukemic
pre-B-cell proliferation followed by the development of a high-grade
B-cell Lymphoma approximately at the age of 6 months [45].
3.2. miRNA-155 and leukemia
Quite recently, O'Connell and others, found increased expression of
miR-155 in bone marrow blasts of leukemic patients bearing M4 or
M5 subtypes of Acute Myeloid Leukemia (AML) [46]. Two experi-
mental models were used in mouse to investigate the possible
relationship between miR-155 and AML. Expanded proliferation of
granulocytes/monocytes in the bone marrow was found in mice
injected with HSCs transduced with miR-155. Moreover, transduction
of miR-155 in cells of the mouse macrophage RAW264.7 line, induces
deregulation of a large number of genes, including 89 genes that were
predicted to be targets of miR-155 on the basis of in silico analysis. Ten
of these target genes (e.g. PU.1 and C/EBPβ) turned out to be involved
in haematopoietic and myeloproliferative disorders [46]. Modulation
of PU.1 may have an oncogenic effect since it could play a role in
differentiation or activation of macrophages and B cells and in the
development of myeloid leukemia [47]. In addition, C/EBPβ is a
transcription factor which plays an important role during heamato-
poietic cell growth and differentiation and has been found to be a
potential target of miR-155 in in vivo AML development [46].
Recent investigations showed that miR-155 is over expressed in
CLL, [48,49]. There are no molecular data on the role of miR-155 in
CLL, although this miRNA appears to be dramatically over expressed,leading to an average up-regulation of 5.3 fold that can peak to 23
fold [48].
3.3. miR-155 and solid tumors
miR-155 gene was found to be over expressed in several solid
tumors, such as thyroid carcinoma [50], breast cancer [17,51,52], colon
cancer [17], cervical cancer [53], pancreatic ductal adenocarcinoma
(PDAC) [54,55], and lung cancer, where it is considered to be a marker
of poor prognosis [17,56,57]. Several studies have recently assessed
the miRNA expression proﬁles of different types of thyroid cancer
[50,58–61]. Thyroid cancer refers to any of the four kinds of malignant
tumors of the thyroid gland: papillary, follicular, medullary or
anaplastic. Nikiforava et al. analyzed frozen tissues from surgically
removed thyroid samples and found that miR-155 was 9.5, 5.5 and
13.2 fold over expressed in papillary, follicular and anaplastic
carcinomas with respect to normal counterpart [50]. Carcinogenic
mutations in thyroid cancer have been well studied. Papillary
carcinomas positive for BRAF, RAS and RET/PTC mutations showed
high expression levels of miR-155, revealing a signiﬁcant relationship
between the presence of this miRNA and those speciﬁc mutations.
Moreover, the authors showed the diagnostic utility of evaluating the
expression levels of some miRNAs in the preoperative assessment of
thyroid nodules in samples obtained from 14 malignant thyroid
tumors. A diagnostically valid assay is important to distinguish thyroid
tumors from normal thyroid tissue and hyperplastic nodules. The
authors analyzed the expression of miR-155 in ﬁne-needle aspiration
samples and found up-regulation of this miRNA in papillary carcinoma
samples compared to hyperplastic nodules [50]. Although further
analyses are needed, these results suggest a diagnostically valid assay
in order to distinguish thyroid tumors from normal thyroid tissue and
hyperplastic nodules.
Two independent studies detected a 10–14 fold up-regulation of
miR-155 in PDAC with respect to normal pancreatic tissue [54,55]. In a
recent work, a loss of TP53INP1 was demonstrated in early stages of
pancreatic cancer. This is a protein known to interact with transcrip-
tional activation of p53 in response to genotoxic stress. Induction of
TP53INP1 over expression in tumor cells is followed by apoptosis and
cell cycle arrest. Surprisingly, in PDAC the mRNA levels of TP53INP1
are similar to those detectable in peritumoral regions, whereas the
protein is almost undetectable in cancer cells. Therefore, these results
point out that miR-155 operates an efﬁcient post-transcriptional
regulation of TP53INP1, as conﬁrmed by transfection experiments. It
follows that the loss of TP53INP1 in PDAC cells is probably due to miR-
155 over expression [36].
4. miR-155 in cardiovascular diseases
The renin–angiotensin system and its effector molecule Angioten-
sin II (Ang II) play an important role in the regulation of hemodynamic
physiological responses such as arteriolar vasoconstriction, blood
pressure, aldosterone production and renal function. Most of the
physiological effects of Ang II are mediated by AT1R.
The expression of the AT1R is regulated predominantly by post-
transcriptional mechanisms. Functional studies have shown that
transfection of miR-155 into human primary lung ﬁbroblasts reduces
the endogenous expression of the AT1R compared with non-
transfected cells. Luciferase report assays showed that miR-155
could directly bind to the 3′UTR of AT1R mRNAs and translationally
represses the protein [62]. Interestingly, a single nucleotide poly-
morphism (+1166 A/C) in the human AT1R was known to be
associated with hypertension, cardiac hypertrophy and myocardial
infarction but its role remained uncertain because it is located within
an untranslated region. This polymorphismwas then found to overlap
with the miR-155 target site in the 3′UTR of AT1R gene (Fig. 2).
Laboratory experiments showed that this polymorphism reduces the
Table 1
Direct targets of miR-155.
Gene symbol Full gene name References
Transcriptional regulatory genes
ARID2 AT rich interactive domain 2 [67]
BACH1 BTB and CNC homology 1, basic leucine zipper
transcription factor1
[46,67]
C/EBPβ CCAAT/enhancer binding protein, beta [46,67]
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 [73]
HIF Hypoxia-inducible factor 1 [46,67]
HIVEP2 Human immunodeﬁciency virus type I enhancer
binding protein 2
[67]
MAF v-maf musculoaponeurotic ﬁbrosarcoma oncogene
homolog (avian)
[28]
MEIS1 Meis homeobox 1 [73]
PU.1 (SPI1) Spleen focus forming virus (SFFV) proviral
integration oncogene spi1
[30,46,67]
SMAD5 SMAD family member 5 [67]
ZIC3 Zic family member 3 [67]
ZNF652 Zinc ﬁnger protein 652 [67]
Protein receptors
AT1R Angiotensin II receptor, type 1 [63,64]
CSF1R Colony stimulating factor 1 receptor [46]
Kinases
IKKɛ Inhibitor of kappa light polypeptide gene
enhancer in B cells, kinase ɛ
[33]
MAP3K7IP2
(TAB2)
Mitogen-activated protein kinase kinase kinase
7 interacting protein 2
[74]
RIPK1 Receptor (TNFRSF)-interacting serine–threonine
kinase 1
[33]
Nuclear proteins
AID Activation-induced cytidine deaminase [31,32]
ARNTL Aryl hydrocarbon receptor nuclear translocator-like [46]
CUTL1 (CUX1) Cut-like homeobox 1 [46]
JARID2 Jumonji, AT rich interactive domain 2 [46]
TP53INP1 Tumor protein p53 induced nuclear protein 1 [36]
Binding proteins
FADD Fas (TNFRSF6)-associated via death domain protein [33]
PICALM Phosphatidylinositol binding clathrin
assembly protein
[46]
RHOA Ras homolog gene family, member A [75]
SLA Scr-like-adaptor [46]
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quently, miR-155 cannot attenuate efﬁciently the translation of the
receptor protein [63]. An additional hint suggesting that miR-155
could be involved in blood pressure regulation stems from the
observation published by Sethupathy [64] on homozygous twins
discordant for trisomy 21. These authors found that the subject with
the extra chromosome over expresses miR-155 and shows impair-
ment of AT1R accompanied by low blood pressure. Altogether, these
results seem to link miR-155 to arterial blood pressure pattern,
suggesting that a deﬁcit of miR-155 function could be implicated in
hypertension and cardiovascular diseases.
5. miR-155 in viral infection
Large experimental evidence is now available showing that
miRNAs are also encoded by viral genomes. To date, known viral
miRNAs derive exclusively from dsDNA viruses (herpesvirus, poly-
omavirus and adenovirus). Nevertheless, for other virus families, the
possibility of encoding miRNAs is not excluded. Viral miRNAs have
been shown to interfere with cellular mRNAs of infected cells
regulating gene expression. Gottwein and colleagues showed that a
miRNA encoded by Kaposi's-sarcoma-associated herpes virus (KSHV)
known as miR-K12-11, functions as an orthologue of cellular miR-155
providing a replicative advantage to the KHSV through the down-
regulation of the expression of genes with known roles in cell growth
and apoptosis [65,66].
BIC/miR-155 expression was analyzed in a panel of Epstein–Barr
virus (EBV) positive B lymphocytes expressing type III and type I
latency genes and in EBV-negative cell lines. The results showed that
the type III EBV-positive cells strongly express miR-155 and that the
induction of miR-155 by EBV contributes to alter gene expression by
targeting a number of transcriptional regulatory genes [67]. The direct
targeting of the transcription factor BACH1 by miR-155 and by its viral
orthologue miR-K12-11 suggests that suppression of BACH1 as well as
that of other miR-155 targets could be a conserved activity of the
members of herpesvirus family.
6. Conclusions
The discovery of RNA interference is one of the major scientiﬁc
breakthroughs in recent years and has revolutionized thewaywe look
at gene regulation, so that the Nobel Prize CC Mello has given his
lecture with the provocative title “Return to the RNA World:
rethinking gene expression and evolution” [68]. It was only in October
of 2001 that three independent groups proposed the term microRNA
for a distinct class of small RNAs implicated in a post-transcriptional
regulatory mechanisms, recognizing that miRNA function could be
more general and important than previously thought [69–71]. After
few years the number of studies on miRNAs has exponentially
increased but the scale of the phenomenon suggests that we are still
at the beginning.
In this review we report the most important results referred to
miR-155 function. It was shown that miR-155 has a distinctive
expression pattern during the different stages of HSC maturation.
Moreover, it has a key role in modulating humoral and cell-mediated
immune response. Mice deﬁcient for miR-155 are apparently normal
during the ﬁrst months after birth. However, later, in the course of
their life, the animals develop lung and intestinal lesions compatible
with a status of immunological dysfunction that was conﬁrmed by
lack of adequate immune response following intravenous sensitiza-
tion with salmonella [28–30]. Worth of note is the ﬁnding that miR-
155 is greatly expressed in activated B, T cells, macrophages and
dendritic cells. In addition the miR-155 down-regulation in erythroid
differentiation suggests a role of this gene in erythropoiesis.
MiR-155 has been also found to be involved in cardiovascular
diseases. Since over expression of this miRNA is accompanied byimpairment of AT1R activity and low blood pressure, it has been
suggested that a deﬁcit of miR-155 function could be implicated in
hypertension. Moreover, miR-155 appears to be involved in biochem-
ical mechanisms associated with viral infections. For example,
induction of miR-155 by EBV contributes to alter gene expression in
infected cells, in part targeting a number of transcriptional regulatory
genes.
To date the world literature has revealed that among the presently
known miRNAs, miR-155 is one of the miRNAs most consistently
involved in neoplastic diseases. Indeed, the frequently detected up-
regulation of miR-155 in malignant cells allows to consider this gene
predominantly as an oncogene playing a role in the pathogenesis of
many human cancers, such as malignancies of the haematopoietic
system (i.e. Hodgkin's Lymphoma, some types of Non Hodgkin's
Lymphoma, AML, and CLL) and solid tumors (i.e. breast, colon,
cervical, pancreatic, lung and thyroid cancer). This hypothesis is
reinforced experimentally by the ﬁnding that over expression of miR-
155 in B cells of transgenic mice induces polyclonal preleukemic B-cell
proliferation followed by overt B-cell Lymphoma [45]. However, as
reported by Dorsett et al. [32], the restrain operated by miR-155 on
AID expression, could also suggest a possible tumor suppression
function of this microRNA in a selected cellular setting. In any case, the
ﬁndings that miR-155 is involved in inﬂammatory processes including
RA [27], appear to highlight a potential link between inﬂammation
and cancer, where the up-regulation of miR-155 could play an
503I. Faraoni et al. / Biochimica et Biophysica Acta 1792 (2009) 497–505important role. As a consequence, rather attractive is the hypothesis
that early resolution of chronic inﬂammation could be followed by
signiﬁcant reduction of carcinogenesis through, at least in part, a
modiﬁcation of miR-155 expression pattern.
Up to now, not entirely elucidated are the mechanisms under-
lying the oncogenic potential or the participation to pathogenesis
of non-neoplastic diseases of miR-155. However, a number of genes
implicated in differentiation, inﬂammation, apoptosis and tran-
scriptional regulation, could be controlled in their expression by
miR-155.
The total number of predicted targets of miR-155 that can be
obtained from the miRBase Sequence database [http://microrna.
sanger.ac.uk] is 991. Moreover, other methods of target prediction,
that are not considered in this data base, can be also used, thus
increasing the number of potential targets. Not all in silico predicted
targets have been found to be responsive to the miRNA upon
experimental validation [72]. Presently, only a limited number of
these genes has been experimentally validated by Luciferase report
assay after transfection with the relevant 3′UTR portion of mRNA, as
summarized in Table 1. Several transcripts of genes coding for
transcriptional regulatory proteins, protein receptors, kinases, nuclear
and DNA binding proteins are the direct targets of miR-155. It follows
that this gene could be now considered an important pleiotropic
regulator of cell homeostasis.
7. Perspectives
Even though the mechanism that regulates miRNA function and
expression has not been completely clariﬁed, the information
presently available (i.e. over expression in a wide type of tumors)
allows us to recognize miR-155 as a gene of paramount clinical
importance either in cancer diagnosis and therapy [56,76]. It is
reasonable to predict that evaluation of mRNA-155 in tissues or
biological ﬂuids could be utilized as a biochemical parameter for
tumor detection and prognosis [18,56,57]. Moreover, a number of
groups have shown that antisense oligonucleotides complementary to
the guide strand of miRNAs named anti-miRNA oligonucleotides
(AMO or antimirs), or antagomirs (when they are conjugated with
cholesterol), can target speciﬁc miRNAs abolishing their function in in
vitro cultured cells, or in vivo in mice and in monkeys [76–79].
Therefore, it could be suggested that an efﬁcacious device able to
down-regulate miR-155 expression in a clinical setting would provide
a novel, and possibly speciﬁc way to control the growth of a wide
range of solid and haematopoietic malignancies in conjunction with
classical cytotoxic therapy. In addition, it was recently demonstrated
that a number of drugs of clinical relevance can modulate in vitro the
miRNA expression in the treated cells thus suggesting that miRNAs
can be suitable targets for therapeutic effects of anticancer agents
[80,81]. We are just at the beginning of a long and still unexplored
avenue of highly promising ﬁeld of molecular investigation. For
example, if one considers the possible role of miR-155 in human
pathology not involving malignant growth, no data are presently
available to suggest whether drugs used in various areas of
therapeutic intervention (e.g. immune-modulating cytokines, hae-
matopoietic factors, anti-inﬂammatory and immune-active agents,
antiviral agents, cardiovascular drugs and other agents acting directly
or indirectly on the functional activity of vital organs) are able to
inﬂuence the expression of this miR gene. Considering the multi-
target inﬂuence afforded by a single miRNA, it is reasonable to
hypothesize that studies directed at establishing the effect of drugs on
miR gene expression (i.e. a novel “pharmacomirnomics” area of
investigation) could disclose possible and up-to now unrevealed
modes of action of drugs. This would appear to be particularly
attractive in those cases in which the pharmacological agents are
known to possess pleiotropic effects that could be explained through a
miRNA-mediated mechanism.Acknowledgments
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